This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Salix Pharmaceuticals, Inc.
Salix Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and focuses primarily on gastrointestinal (GI) disorders. Founded in 2001, Salix has established itself as a leader in developing innovative therapies that address unmet medical needs in the GI space. The company’s core products, including treatments for conditions such as irritable bowel syndrome and inflammatory bowel disease, are distinguished by their efficacy and patient-centric approach. With a strong market position, Salix has achieved significant milestones, including the successful launch of several key medications that have transformed patient care. The company’s commitment to research and development, alongside its strategic partnerships, has solidified its reputation as a trusted provider of specialised GI therapies, making it a vital contributor to the healthcare landscape.
DitchCarbon Score
How does Salix Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Salix Pharmaceuticals, Inc.'s score of 40 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Salix Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of Bausch Health Companies Inc., which means that any emissions data or climate commitments would be cascaded from this parent organisation. As part of its climate strategy, Salix Pharmaceuticals inherits initiatives and targets from Bausch Health Companies Inc. at a cascade level of three. However, there are no documented reduction targets or specific climate pledges available for Salix Pharmaceuticals at this time. This lack of data suggests that the company may still be in the process of establishing its own distinct climate commitments or may rely on the broader corporate strategies of its parent company. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of addressing climate change and reducing carbon footprints. While Salix Pharmaceuticals has not yet reported specific emissions or targets, it is essential for organisations in this sector to align with industry standards and best practices to contribute to global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 46,686,000 | 00,000,000 |
| Scope 2 | 50,513,000 | 00,000,000 |
| Scope 3 | 19,260,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Salix Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
